Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Percutaneous Image-Guided Breast Biopsy To Receive Unique Coding By April

This article was originally published in The Gray Sheet

Executive Summary

Percutaneous image-guided breast biopsy procedures will be assigned unique payment and coding by the Health Care Financing Administration by April 2000, agency staffers predict following the release of a Medicare coverage decision memorandum.

You may also be interested in...



Greenwood Serves Notice To CMS On Image-Guided Breast Biopsy Payments

The Centers for Medicare & Medicaid Services should provide an explanation of the data and process by which it set reimbursement levels for image-guided breast biopsy procedures to the House Commerce Committee by Oct. 30, Rep. Jim Greenwood (R-Penn.) states in an Oct. 16 letter to administrator Tom Scully.

Greenwood Serves Notice To CMS On Image-Guided Breast Biopsy Payments

The Centers for Medicare & Medicaid Services should provide an explanation of the data and process by which it set reimbursement levels for image-guided breast biopsy procedures to the House Commerce Committee by Oct. 30, Rep. Jim Greenwood (R-Penn.) states in an Oct. 16 letter to administrator Tom Scully.

Image-Guided Breast Biopsy Coverage Raises Palpable Fears For Surgeons

The Health Care Financing Administration will have to decide between two conflicting position statements in rendering a coverage decision on percutaneous image-guided breast biopsy for palpable lesions.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel